NewLeaf Symbiotics
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Total Raised
$113.4MInvestors Count
14Deal Terms
2NewLeaf Symbiotics Funding, NewLeaf Symbiotics Valuation & NewLeaf Symbiotics Revenue
11 Fundings
NewLeaf Symbiotics's latest funding round was a Debt - IV for $10M on December 13, 2021.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/13/2021 | Debt - IV | $10M | Undisclosed Investors | 1 | ||
12/1/2020 | Series D - II | $22M | 2 | |||
4/15/2020 | Loan | $0.68M | ||||
2/24/2020 | Series D | |||||
1/8/2020 | Debt - III |
Date | 12/13/2021 | 12/1/2020 | 4/15/2020 | 2/24/2020 | 1/8/2020 |
|---|---|---|---|---|---|
Round | Debt - IV | Series D - II | Loan | Series D | Debt - III |
Amount | $10M | $22M | $0.68M | ||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 | 2 |
NewLeaf Symbiotics Deal Terms
2 Deal Terms
NewLeaf Symbiotics's deal structure is available for 2 funding rounds, including their Series B from September 15, 2014.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
NewLeaf Symbiotics Investors
14 Investors
NewLeaf Symbiotics has 14 investors. RockPort Capital Partners invested in NewLeaf Symbiotics's Series D - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1/9/2013 | 12/1/2020 | 5 Series A, Series B (2014), Series C (2017), Series D (2020), Series D - II (2020) | Kevin Kopczynski | Venture Capital | Massachusetts | |
9/15/2014 | 12/1/2020 | 4 Series B, Series C (2017), Series D (2020), Series D - II (2020) | John Pasquesi | Private Equity | California | |
9/7/2017 | 12/1/2020 | 3 Series C - II, Series D (2020), Series D - II (2020) | Venture Capital | Illinois | ||
Corporate Venture | Germany | |||||
Corporation | Kansas |
First funding | 1/9/2013 | 9/15/2014 | 9/7/2017 | ||
|---|---|---|---|---|---|
Last Funding | 12/1/2020 | 12/1/2020 | 12/1/2020 | ||
Investor | |||||
Rounds | 5 Series A, Series B (2014), Series C (2017), Series D (2020), Series D - II (2020) | 4 Series B, Series C (2017), Series D (2020), Series D - II (2020) | 3 Series C - II, Series D (2020), Series D - II (2020) | ||
Board Seats | Kevin Kopczynski | John Pasquesi | |||
Type | Venture Capital | Private Equity | Venture Capital | Corporate Venture | Corporation |
Location | Massachusetts | California | Illinois | Germany | Kansas |
NewLeaf Symbiotics Acquisitions
1 Acquisition
NewLeaf Symbiotics acquired 1 company. Their latest acquisition was Intuitive Genomics on December 06, 2013.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/6/2013 | Acquired | 1 |
Date | 12/6/2013 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.